| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia H Kantarjian, Y Oki, G Garcia-Manero, X Huang, S O'Brien, J Cortes, ... Blood 109 (1), 52-57, 2007 | 972 | 2007 |
| Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia W Wierda, S O’Brien, S Wen, S Faderl, G Garcia-Manero, D Thomas, ... Journal of clinical oncology 23 (18), 4070-4078, 2005 | 698 | 2005 |
| High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia H Kantarjian, M Talpaz, S O'Brien, G Garcia-Manero, S Verstovsek, ... Blood 103 (8), 2873-2878, 2004 | 561 | 2004 |
| Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes G Garcia-Manero, H Yang, C Bueso-Ramos, A Ferrajoli, J Cortes, ... Blood, The Journal of the American Society of Hematology 111 (3), 1060-1066, 2008 | 548 | 2008 |
| Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia A Ferrajoli, BN Lee, EJ Schlette, SM O'Brien, H Gao, S Wen, WG Wierda, ... Blood, The Journal of the American Society of Hematology 111 (11), 5291-5297, 2008 | 526 | 2008 |
| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 505 | 2019 |
| Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia E Estey, G Garcia-Manero, A Ferrajoli, S Faderl, S Verstovsek, D Jones, ... Blood 107 (9), 3469-3473, 2006 | 476 | 2006 |
| Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin F Ravandi, E Estey, D Jones, S Faderl, S O'Brien, J Fiorentino, S Pierce, ... Journal of Clinical Oncology 27 (4), 504-510, 2009 | 465 | 2009 |
| Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome–negative precursor B-lineage acute lymphoblastic leukemia DA Thomas, S O'Brien, S Faderl, G Garcia-Manero, A Ferrajoli, W Wierda, ... Journal of Clinical Oncology 28 (24), 3880-3889, 2010 | 464 | 2010 |
| microRNA therapeutics in cancer—an emerging concept MY Shah, A Ferrajoli, AK Sood, G Lopez-Berestein, GA Calin EBioMedicine 12, 34-42, 2016 | 457 | 2016 |
| Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia WG Wierda, S O'Brien, X Wang, S Faderl, A Ferrajoli, KA Do, J Cortes, ... Blood, The Journal of the American Society of Hematology 109 (11), 4679-4685, 2007 | 447 | 2007 |
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study JA Burger, MJ Keating, WG Wierda, E Hartmann, J Hoellenriegel, ... The Lancet Oncology 15 (10), 1090-1099, 2014 | 431 | 2014 |
| First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic … F Ravandi, S O'Brien, D Thomas, S Faderl, D Jones, R Garris, S Dara, ... Blood, The Journal of the American Society of Hematology 116 (12), 2070-2077, 2010 | 401 | 2010 |
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib P Jain, M Keating, W Wierda, Z Estrov, A Ferrajoli, N Jain, B George, ... Blood, The Journal of the American Society of Hematology 125 (13), 2062-2067, 2015 | 385 | 2015 |
| Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies KWL Yee, Z Zeng, M Konopleva, S Verstovsek, F Ravandi, A Ferrajoli, ... Clinical Cancer Research 12 (17), 5165-5173, 2006 | 379 | 2006 |
| Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma DA Thomas, S O'Brien, J Cortes, FJ Giles, S Faderl, S Verstovsek, ... Blood 104 (6), 1624-1630, 2004 | 334 | 2004 |
| Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase JE Cortes, D Jones, S O'Brien, E Jabbour, M Konopleva, A Ferrajoli, ... Journal of Clinical Oncology 28 (3), 392-397, 2010 | 312 | 2010 |
| Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies S Faderl, DA Thomas, S O'Brien, G Garcia-Manero, HM Kantarjian, ... Blood, The Journal of the American Society of Hematology 101 (9), 3413-3415, 2003 | 309 | 2003 |
| The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute … FJ Giles, G Borthakur, F Ravandi, S Faderl, S Verstovsek, D Thomas, ... British journal of haematology 136 (4), 624-627, 2007 | 303 | 2007 |
| Complex karyotype is a stronger predictor than del (17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based … PA Thompson, SM O'Brien, WG Wierda, A Ferrajoli, F Stingo, SC Smith, ... Cancer 121 (20), 3612-3621, 2015 | 290 | 2015 |
